Operating Lease, Right-of-Use Asset of Anika Therapeutics, Inc. from 31 Mar 2019 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
Anika Therapeutics, Inc. quarterly Operating Lease, Right-of-Use Asset in USD history and change rate from 31 Mar 2019 to 30 Sep 2025.
  • Anika Therapeutics, Inc. Operating Lease, Right-of-Use Asset for the quarter ending 30 Sep 2025 was $24,226,000, a 11% decline year-over-year.
Source SEC data
View on sec.gov
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Change (%)

Anika Therapeutics, Inc. Quarterly Operating Lease, Right-of-Use Asset (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $24,226,000 -$2,982,000 -11% 30 Sep 2025 10-Q 05 Nov 2025 2025 Q3
Q2 2025 $24,722,000 -$3,043,000 -11% 30 Jun 2025 10-Q 30 Jul 2025 2025 Q2
Q1 2025 $25,180,000 -$3,001,000 -11% 31 Mar 2025 10-Q 09 May 2025 2025 Q1
Q4 2024 $25,685,000 -$1,869,000 -6.8% 31 Dec 2024 10-Q 05 Nov 2025 2025 Q3
Q3 2024 $27,208,000 -$1,845,000 -6.4% 30 Sep 2024 10-Q 04 Nov 2024 2024 Q3
Q2 2024 $27,765,000 -$1,866,000 -6.3% 30 Jun 2024 10-Q 08 Aug 2024 2024 Q2
Q1 2024 $28,181,000 -$1,994,000 -6.6% 31 Mar 2024 10-Q 08 May 2024 2024 Q1
Q4 2023 $27,554,000 -$3,142,000 -10% 31 Dec 2023 10-K 17 Mar 2025 2024 FY
Q3 2023 $29,053,000 -$1,934,000 -6.2% 30 Sep 2023 10-Q 03 Nov 2023 2023 Q3
Q2 2023 $29,631,000 -$1,976,000 -6.3% 30 Jun 2023 10-Q 08 Aug 2023 2023 Q2
Q1 2023 $30,175,000 +$9,658,000 +47% 31 Mar 2023 10-Q 09 May 2023 2023 Q1
Q4 2022 $30,696,000 +$9,739,000 +46% 31 Dec 2022 10-K 15 Mar 2024 2023 FY
Q3 2022 $30,987,000 +$9,590,000 +45% 30 Sep 2022 10-Q 09 Nov 2022 2022 Q3
Q2 2022 $31,607,000 +$9,758,000 +45% 30 Jun 2022 10-Q 04 Aug 2022 2022 Q2
Q1 2022 $20,517,000 -$1,808,000 -8.1% 31 Mar 2022 10-Q 06 May 2022 2022 Q1
Q4 2021 $20,957,000 -$1,662,000 -7.3% 31 Dec 2021 10-K 16 Mar 2023 2022 FY
Q3 2021 $21,397,000 -$1,501,000 -6.6% 30 Sep 2021 10-Q 05 Nov 2021 2021 Q3
Q2 2021 $21,849,000 -$1,347,000 -5.8% 30 Jun 2021 10-Q 06 Aug 2021 2021 Q2
Q1 2021 $22,325,000 -$1,203,000 -5.1% 31 Mar 2021 10-Q 07 May 2021 2021 Q1
Q4 2020 $22,619,000 -$245,000 -1.1% 31 Dec 2020 10-K 11 Mar 2022 2021 FY
Q3 2020 $22,898,000 -$184,000 -0.8% 30 Sep 2020 10-Q 05 Nov 2020 2020 Q3
Q2 2020 $23,196,000 -$299,000 -1.3% 30 Jun 2020 10-Q 07 Aug 2020 2020 Q2
Q1 2020 $23,528,000 -$220,000 -0.93% 31 Mar 2020 10-Q 22 May 2020 2020 Q1
Q4 2019 $22,864,000 31 Dec 2019 10-K/A 26 Apr 2021 2020 FY
Q3 2019 $23,082,000 30 Sep 2019 10-Q 28 Oct 2019 2019 Q3
Q2 2019 $23,495,000 30 Jun 2019 10-Q 26 Jul 2019 2019 Q2
Q1 2019 $23,748,000 31 Mar 2019 10-Q 06 May 2019 2019 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.